8-K - Tarsus Pharmaceuticals, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Tarsus Pharmaceuticals, Inc. expanded its Board of Directors from seven to eight members and appointed David E.I. Pyott as a Class III director, effective February 18, 2026. Mr. Pyott was also appointed Chairperson of the Commercial Committee and member of the Nominating and Compensation Committees, with an initial equity grant valued at $540,000.

Key Takeaways

1Board expanded from 7 to 8 directors on February 18, 2026

2David E.I. Pyott appointed as Class III director with term expiring at 2026 annual meeting

3Mr. Pyott appointed Chairperson of Commercial Committee and member of Nominating and Compensation Committees

4Mr. Pyott determined independent under Nasdaq and SEC standards

5Initial compensation grant of $540,000 (50% options, 50% RSUs) per non-employee director policy

6Entered into indemnification agreement with Mr. Pyott

Current Report Details

Event Type

Management Change

Exhibits Only

Disclosure

Mandatory

Variant

8-K

Items Reported

5.02

. Departure of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officers. On February

Management Change

$540.0KMr. Pyott in connection with his appointment to the Board, which is in substantially the same form as that entered into with the other directors of the Company

9.01

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1 Form of Indemnity Agreement (incorporated by reference to Exhibit 10.1 to the Comp

Exhibits Only

Source Document

Executive & Director Changes

David E.I. Pyott

Class III Director; Chairperson of Commercial Committee; Member of Nominating Committee and Compensation Committee

Appointed

Effective: 2026-02-18

Exhibits (2)

8-K

99.1

EX-99.1